A Phase I/II Dose Escalation study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine for patients with metastatic melanoma.

Trial Profile

A Phase I/II Dose Escalation study of the tumor-targeting human L19-IL2 monoclonal antibody-cytokine fusion protein in combination with Dacarbazine for patients with metastatic melanoma.

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs L19-IL2 fusion protein (Primary) ; Dacarbazine
  • Indications Malignant melanoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Philogen
  • Most Recent Events

    • 27 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Jun 2017.
    • 05 Oct 2016 Planned End Date changed from 1 Aug 2016 to 1 Dec 2016.
    • 05 Oct 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top